Adc Therapeutics Sa (ADCT) Earnings Report, Financial Results, Financial analysis

Adc Therapeutics Sa narrowed forth quarter of 2022 net loss per share of $-1.99 compare to net loss per share of $-6.00 recorded in the same quarter a year ago a decrease compare to $0.00 realized in previous quarter.

*forth quarter of 2022*
Earnings Per Share	Revenues
$ -1.99	$ 210 Mill
$+4.01	$+176M +518.89 %

Adc Therapeutics Sa's Revenue rose by 518.89 % in forth quarter of 2022 (Dec 31 2022) year on year, to $210 million and advanced by sequentially.

Adc Therapeutics Sa is Expected to report next financial results on March 14, 2024.

More on ADCT's Income Statement

ADCT's NET INCOME

Adc Therapeutics Sa's in theforth quarter of 2022 recorded net loss of $-155.800 million, an improvement compare to net loss of $-230.026 million in IV. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $0.000 million in the previous quarter.

More on ADCT's Growth

Adc Therapeutics Sa Inventories
In Dec 31 2022 company's net cash and cash equivalents decreased by $0 million

Earnings quality

Adc Therapeutics Sa does not pay out common stock dividend.

In trailing twelve-month period Adc Therapeutics Sa payed $ -3.08 cash per share, on a free-cash flow basis .

Book value fell by 0.00 % sequentially to $1.13 per share.
Tangible Book value fell to $ 1.13 per share from $ 1.13.

Company repurchased 0.00 million shares or 0.00 % in Dec 31 2022.

• More on ADCT's Dividends

Market Capitalization (Millions)	197
Shares Outstanding (Millions)	78
Total Debt (Millions $)	97
Revenue (TTM) (Millions $)	210
Net Income (TTM) (Millions $)	-156
Cash Flow (TTM) (Millions $)	0
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	9,050

Earnings quality

Adc Therapeutics Sa does not pay out common stock dividend.

In trailing twelve-month period Adc Therapeutics Sa had negative $ -3.08 cash flow per share, on a free-cash flow basis .

Book value fell by 0.00 % sequentially to $1.13 per share.
Tangible Book value fell to $ 1.13 per share from $ 1.13.

Company repurchased 0.00 million shares or 0.00 % in Dec 31 2022.

• More on ADCT's Balance Sheets

Market Capitalization (Millions)	197
Shares Outstanding (Millions)	78
Total Debt (Millions $)	97
Revenue (TTM) (Millions $)	210
Net Income (TTM) (Millions $)	-156
Cash Flow (TTM) (Millions $)	0
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	9,050

Adc Therapeutics Sa

ADCT's Financial Statements and Analysis